These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2979265)
81. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. Kukanich B; Lascelles BD; Aman AM; Mealey KL; Papich MG J Vet Pharmacol Ther; 2005 Oct; 28(5):461-6. PubMed ID: 16207309 [TBL] [Abstract][Full Text] [Related]
82. Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Marino G; Rustgi VK; Salzberg G; Johnson LB; Kuo PC; Plotkin JS; Flockhart DA Aliment Pharmacol Ther; 2002 Feb; 16(2):235-42. PubMed ID: 11860406 [TBL] [Abstract][Full Text] [Related]
83. Prescribing for patients with liver disease. Arns PA; Branch RA Baillieres Clin Gastroenterol; 1989 Jan; 3(1):109-30. PubMed ID: 2655746 [No Abstract] [Full Text] [Related]
84. Safe use of proton pump inhibitors in patients with cirrhosis. Weersink RA; Bouma M; Burger DM; Drenth JPH; Harkes-Idzinga SF; Hunfeld NGM; Metselaar HJ; Monster-Simons MH; van Putten SAW; Taxis K; Borgsteede SD Br J Clin Pharmacol; 2018 Aug; 84(8):1806-1820. PubMed ID: 29688583 [TBL] [Abstract][Full Text] [Related]
85. Effects of liver disease on pharmacokinetics. An update. Rodighiero V Clin Pharmacokinet; 1999 Nov; 37(5):399-431. PubMed ID: 10589374 [TBL] [Abstract][Full Text] [Related]
86. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Andersson T Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397 [TBL] [Abstract][Full Text] [Related]
87. Pharmacokinetics of intravenous omeprazole in children. Jacqz-Aigrain E; Bellaich M; Faure C; Andre J; Rohrlich P; Baudouin V; Navarro J Eur J Clin Pharmacol; 1994; 47(2):181-5. PubMed ID: 7859807 [TBL] [Abstract][Full Text] [Related]